Genmab A/S (GMAB) Stock

Media Release COPENHAGEN, Denmark; January 03, 2025 Genmab A/S (Nasdaq: GMAB) has announced that its CEO, Jan van de Winkel, Ph.D., will give a company update at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for January 14, 2025, at 3:00 PM PST / 6:00 PM EST, which is 12:00 AM CET on January 15, 2025. You can watch the live and recorded webcast on Genmab's website at https://ir.genmab.com/events-presentations.

A virtual media release event will be hosted by Genmab A/S today, December 11, 2024, at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The 2024 R&D Update and ASH Data Review Meeting will be conducted in English and can be accessed through a live webcast. The event will also be available for later viewing on www.genmab.com.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) has shared new long-term findings from two ongoing clinical trials that are testing epcoritamab, a bispecific antibody that engages T-cells, given as a subcutaneous injection to adult patients with diffuse large B-cell lymphoma (DLBCL). The results come from Arm 1 of the Phase 1b/2 EPCORE® NHL-2 trial (NCT04663347), which is assessing the fixed-duration use of epcoritamab alongside rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) has shared early results from the EPCORE® CLL-1 trial, showing an overall response rate (ORR) of 61 percent and a complete response (CR) rate of 39 percent in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who had already undergone multiple treatments. Among those who responded to the treatment, 75 percent had no detectable minimal residual disease (MRD), meaning they showed no signs of the disease after treatment.

Genmab's stock has dropped to appealing levels that are difficult to overlook. This year, the company is projected to earn over $2.5 billion in royalty revenues, with the possibility of reaching $4 billion at its highest point, mainly due to Darzalex and Kesimpta. Even with some challenges and worries in the market, Genmab's long-term growth outlook is promising, backed by increasing Epkinly revenues, a broader clinical pipeline, and the purchase of ProfoundBio.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) has reported impressive results for patients with relapsed or refractory follicular lymphoma. The treatment combining epcoritamab with lenalidomide and rituximab showed a 96 percent overall response rate, an 87 percent complete response rate, and an 80 percent progression-free survival rate over 21 months. Additionally, long-term follow-up indicated a strong two-year overall survival rate of 90 percent.

Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will raise its share capital by 10,355 shares due to the exercise of employee warrants. This increase will happen without giving existing shareholders or others any preemption rights.

Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) – This document shares information about transactions conducted by managerial staff and their close associates at Genmab A/S (Nasdaq: GMAB), in line with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.

Media Release COPENHAGEN, Denmark; November 25, 2024 Genmab A/S (Nasdaq: GMAB) has announced that its Chief Financial Officer, Anthony Pagano, will participate in a fireside chat at Citi's 2024 Global Healthcare Conference on December 3, 2024, at 8:30 PM CET / 2:30 PM EST. You can watch the event live on Genmab's website at https://ir.genmab.com/events-presentations.